Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor
Copyright 1999 American Medical Association.
All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
In Reply: Our study of
patients with CFS was designed to evaluate efficacy and safety of
hydrocortisone.1 We reported that divided doses totaling 25
to 35 mg/d for 12 weeks provided significant but modest symptomatic
relief and also significant adrenal suppression. Our conclusion, then
and now, is that the risks associated with low-dose hydrocortisone
treatment outweigh its potential advantages for patients with CFS.
Straus SE, McKenzie R, Demitrack MA. Low-Dose Hydrocortisone for Chronic Fatigue Syndrome—Reply. JAMA. 1999;281(20):1887-1889. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-20-jbk0526